Published TCIMAIL newest issue No.197 | New tool "TCI SpectraViewer" | [TCIPracticalExample] 2,2,2-Trifluoroethyl Etherification Using... | Product Document Searching Made Easy by 2D Code!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 150322-43-3 | Product Number: P2040
Prasugrel
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl Acetate
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 200MG |
₹7,700.00
|
2 | 14 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | P2040 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__0H__2__0FNO__3S = 373.44 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 150322-43-3 |
| Reaxys Registry Number | 9008623 |
| PubChem Substance ID | 172089108 |
| MDL Number | MFCD09954140 |
Specifications
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 120.0 to 124.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 122 °C |
GHS
Related Laws:
Transport Information:
Application
Studies on the Platelet Aggregation Inhibition Activity of Prasugel
References
- Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
- Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
- Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
- Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
- The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.